H. Wildiers
Molecular Biology · 2004–2021
A researcher in the Science corpus: 7 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 45 citations into it
Whom H. Wildiers trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- Peter Carmeliet (in Molecular Biology)
Papers from H. Wildiers's perspective
Ordered by how strongly the researchers H. Wildiers trusts endorse each paper. Same corpus, a different order for every researcher.
- Tumor angiogenesis: past, present and the near future. (Carcinogenesis)
- Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. (Journal of Clinical Oncology)
- Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). (Critical reviews in oncology/hematology)
- Methodological index for non‐randomized studies (MINORS): development and validation of a new instrument (ANZ journal of surgery)
- Improving the Quality of Spiritual Care as a Dimension of Palliative Care: The Report of the Consensus Conference (Journal of Palliative Medicine)
- Mechanisms of angiogenesis and arteriogenesis (Nature Medicine)
- Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis (Nature Cell Biology)
- Clinical translation of angiogenesis inhibitors (Nature Reviews. Cancer)
- A Comparison of Frailty Indexes for the Prediction of Falls, Disability, Fractures and Mortality in Older Men (Journal of The American Geriatrics Society)
- Comparison of 2 frailty indexes for prediction of falls, disability, fractures, and death in older women. (Archives of Internal Medicine)
Their papers
- Vascular Endothelial Growth Factor and Angiogenesis (2004) — 1,932 citations
- A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer (2021) — 664 citations
- MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2− metastatic breast cancer (2017) — 605 citations
- Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†. (2015) — 708 citations
- Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. (2014) — 652 citations
- International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. (2014) — 1,582 citations
- Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. (2011) — 700 citations